Edition:
India

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

44.89USD
1:30am IST
Change (% chg)

$1.75 (+4.06%)
Prev Close
$43.14
Open
$43.05
Day's High
$44.89
Day's Low
$43.05
Volume
198,727
Avg. Vol
341,155
52-wk High
$52.95
52-wk Low
$14.57

Latest Key Developments (Source: Significant Developments)

Ptc Therapeutics Inc Qtrly Revenue $68.7 Million
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - PTC Therapeutics Inc ::PTC THERAPEUTICS INC QTRLY TOTAL REVENUE $68.7 MILLION, COMPARED TO $48.0 MILLION.PTC THERAPEUTICS - 2018 NET PRODUCT REVENUES ARE ANTICIPATED TO BE BETWEEN $260 AND $295 MILLION.PTC THERAPEUTICS INC QTRLY LOSS PER SHARE $0.21.  Full Article

Akcea Therapeutics, PTC Therapeutics Collaborate To Commercialize Two Rare Disease Drugs In Latin America
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Akcea Therapeutics Inc ::AKCEA THERAPEUTICS AND PTC THERAPEUTICS COLLABORATE TO COMMERCIALIZE TWO RARE DISEASE DRUGS IN LATIN AMERICA.AKCEA THERAPEUTICS - PTC TO COMMERCIALIZE 2 OF CO'S RARE DISEASE DRUGS IN LATAM: TEGSEDI (INOTERSEN) AND WAYLIVRA (VOLANESORSEN).AKCEA THERAPEUTICS INC - PTC WILL GAIN EXCLUSIVE RIGHTS TO TEGSEDI AND WAYLIVRA IN LATIN AMERICA AND CERTAIN CARIBBEAN COUNTRIES.AKCEA THERAPEUTICS INC - PTC WILL PAY AKCEA AN UPFRONT LICENSING FEE OF $18 MILLION, $12 MILLION.AKCEA THERAPEUTICS INC - UPFRONT LICENSING FEE IS DUE ON SIGNING AND $6 MILLION WHICH WILL BE PAID ON EARLIER OF FDA OR EMA APPROVAL OF WAYLIVRA.AKCEA THERAPEUTICS INC - PTC WILL PAY AKCEA REGULATORY MILESTONES IN PTC TERRITORY UP TO A TOTAL OF $8 MILLION.AKCEA THERAPEUTICS INC - CO IS ALSO ELIGIBLE TO RECEIVE ROYALTIES FROM PTC IN MID-TWENTY PERCENT RANGE ON NET SALES OF EACH DRUG IN PTC TERRITORY.AKCEA THERAPEUTICS INC - COLLABORATION WILL BE GOVERNED BY A JOINT STEERING COMMITTEE WITH REPRESENTATION FROM BOTH PARTIES.  Full Article

PTC Therapeutics Says Co Entered Into A Bridge Loan And Security Agreement
Friday, 20 Jul 2018 

July 19 (Reuters) - PTC Therapeutics Inc ::PTC THERAPEUTICS INC SAYS IN CONNECTION WITH MERGER AGREEMENT WITH AGILIS, CO ENTERED INTO A BRIDGE LOAN AND SECURITY AGREEMENT - SEC FILING.PTC THERAPEUTICS INC - UNDER BRIDGE LOAN AGREEMENT, CO AGREED TO MAKE TERM LOAN ADVANCE TO AGILIS IN AN ORIGINAL PRINCIPAL AMOUNT OF UP TO $10 MILLION.PTC THERAPEUTICS - ALSO, UNDER AGREEMENT IF DEAL DOES NOT CLOSE BEFORE SEPT 2, CO TO ADVANCE ADDITIONAL TERM LOAN OF UP TO $10 MILLION TO AGILIS.  Full Article

D. E. Shaw & Co Reports 5 Pct Passive Stake In PTC Therapeutics
Wednesday, 30 May 2018 

May 29 (Reuters) - PTC Therapeutics Inc ::D. E. SHAW & CO., L.P REPORTS A 5.0 PERCENT PASSIVE STAKE IN PTC THERAPEUTICS AS OF MAY 16, 2018 - SEC FILING.  Full Article

PTC Therapeutics Prices Public Offering Of Common Stock At $27.04 Per Share​
Thursday, 29 Mar 2018 

March 28 (Reuters) - Ptc Therapeutics Inc ::PTC THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.‍PRICING OF A PUBLIC OFFERING OF 4,000,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $27.04 PER SHARE​.  Full Article

PTC Therapeutics reports qtrly net loss per share basic and diluted of $0.82
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Ptc Therapeutics Inc ::Qtrly total revenues $41.9 million versus $22.98 million.Qtrly net loss per share basic and diluted $0.82.Q3 earnings per share view $-0.68, revenue view $42.2 million -- Thomson Reuters I/B/E/S.Increasing 2017 revenue guidance to $160-$185M​.FY2017 revenue view $173.4 million -- Thomson Reuters I/B/E/S.  Full Article

Camber Capital Management LLC reports 5.84 pct passive stake in PTC Therapeutics
Thursday, 29 Sep 2016 

Camber Capital Management LLC:Camber Capital Management LLC reports 5.84 pct passive stake in PTC Therapeutics Inc as of Sept. 19 - SEC filing.  Full Article

Roche SMA drug shines in study as costly new therapies advance

ZURICH A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive.